VEGFA and neoplasm: Bevacizumab, an anti-VEGF antibody to reduce tumor angiogenesis, was found to induce tumor hypoxia and upregulation of hypoxia-inducible factor-1α (HIF1α), resulting in hypoxia-induced resistance to bevacizumab in tumors [78].